KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Receivables (2016 - 2025)

Arbutus Biopharma's Change in Receivables history spans 13 years, with the latest figure at -$120000.0 for Q3 2025.

  • For Q3 2025, Change in Receivables rose 24.53% year-over-year to -$120000.0; the TTM value through Sep 2025 reached -$703000.0, down 24.87%, while the annual FY2024 figure was $633000.0, 49.29% up from the prior year.
  • Change in Receivables for Q3 2025 was -$120000.0 at Arbutus Biopharma, up from -$157000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.3 million in Q1 2023 and bottomed at -$1.2 million in Q1 2025.
  • The 5-year median for Change in Receivables is -$120000.0 (2025), against an average of -$21421.1.
  • The largest annual shift saw Change in Receivables surged 1890.91% in 2022 before it tumbled 644.0% in 2024.
  • A 5-year view of Change in Receivables shows it stood at -$768000.0 in 2021, then soared by 37.11% to -$483000.0 in 2022, then grew by 18.22% to -$395000.0 in 2023, then soared by 302.78% to $801000.0 in 2024, then crashed by 114.98% to -$120000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Change in Receivables are -$120000.0 (Q3 2025), -$157000.0 (Q2 2025), and -$1.2 million (Q1 2025).